Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models

Previous studies have shown that increased levels of chemokine receptor CXCR7 are associated with the increased invasiveness of prostate cancer cells. We now show that CXCR7 expression is upregulated in VCaP and C4‐2B cells after enzalutamide (ENZ) treatment. ENZ treatment induced apoptosis (sub‐G1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Yong, Azad, Abul Kalam, Karanika, Styliani, Basourakos, Spyridon P., Zuo, Xuemei, Wang, Jianxiang, Yang, Luan, Yang, Guang, Korentzelos, Dimitrios, Yin, Jianhua, Park, Sanghee, Zhang, Penglie, Campbell, James J., Schall, Thomas J., Cao, Guangwen, Li, Likun, Thompson, Timothy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867246/
https://www.ncbi.nlm.nih.gov/pubmed/29277895
http://dx.doi.org/10.1002/ijc.31237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867246/
https://www.ncbi.nlm.nih.gov/pubmed/29277895
http://dx.doi.org/10.1002/ijc.31237

Ejemplares similares